Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Affiliations

• ¹ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rnamaria@mdanderson.org.
• ² Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
• ³ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁴ Department of Pathology, The University of California San Francisco, San Francisco, CA, USA.
• ⁵ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, US.
• ⁶ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁷ Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁸ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁹ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ¹⁰ Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹¹ Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ¹² Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.